Sorafenib Accord

Sorafenib Accord is a cancer medicine used to treat patients who have the following diseases: - hepatocellular carcinoma (a type of liver cancer); - advanced renal cell carcinoma (a type of kidney cancer) when cancer treatment with interferon alpha or interleukin-2 has failed or cannot be used; Sorafenib Accord contains the active substance sorafenib. Sorafenib Accord is a ‘generic medicine’. This means that Sorafenib Accord contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Nexavar. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-generic-medicines_en.pdf).